Kite, a Gilead Company, shared data showing that Yescarta continues to benefit patients with relapsed/refractory large B-cell lymphoma as a second-line therapy. Results from the ZUMA-7 and ALYCANTE studies revealed promising overall survival rates of 64.9% and 70.8%, respectively, after two years. Event-free survival rates were also strong at 45.2%, and progression-free survival rates were 47.4%. Additional findings showed high rates of complete metabolic response and overall response, with a majority of patients maintaining their response at 12 months. These results highlight the positive impact of Yescarta on patients with R/R LBCL.

Read more at Nasdaq: Kite’s Yescarta Shows Durable Benefits In R/R Large B-Cell Lymphoma Across Phase 3 & Phase 2 Studies